-
Mashup Score: 3
Standard first-line chemotherapy for patients with small cell lung cancer (SCLC) consists of a platinum salt (carboplatin or cisplatin) in combination with etoposide [1,2]. Recently, atezolizumab [3] or durvalumab [4] plus carboplatin/etoposide showed improved survival compared to chemotherapy alone, and both have been approved by the US FDA as first-line therapy. However, therapeutic options are…
Source: Lung CancerCategories: Hem/Oncs, Latest HeadlinesTweet
-
Mashup Score: 1Alectinib for the treatment of pretreated RET-rearranged advanced NSCLC: results of the ETOP ALERT-lung trial - 2 year(s) ago
RET-fusions in non-small cell lung cancer (NSCLC) were first detected in 2012. The most frequent fusion partner of the RET–gene in lung cancer is KIF5B. Overall, 48 fusion partners have been identified.[1] RET-fusions can be detected in 1-2% of lung adenocarcinomas.[2]
Source: Lung CancerCategories: Hem/Oncs, Latest HeadlinesTweet-
Alectinib is an excellent #ALK inhibitor but also had #RET activity in vitro. A prospective phase II (ETOP-ALERT) studied alectinib in RET+ NSCLC and showed no responses. Study closed due to lack of efficacy (and better RET TKIs). Reported @LungCaJournal. https://t.co/steLlfzExj
-
-
Mashup Score: 0
Until the introduction of immunotherapy, platinum-based chemotherapy was the first-line standard of care in advanced or metastatic nonsquamous non-small cell lung cancer (NSCLC) without genomic tumor alterations per international NSCLC treatment guidelines (NCCN 2021).1 With the substantial advances made in immunotherapy-based therapeutic approaches either as monotherapy or in combination with…
Source: Lung CancerCategories: Hem/Oncs, Latest HeadlinesTweet-
Final OS data from the phase III ORIENT-11 study of 1L sintilimab (anti-PD1) + platinum/pemetrexed in nonsquamous #NSCLC in @LungCaJournal. With 30m f/u and 47% crossover, OS favors sintilimab + chemo (24.2 vs 16.8m, HR 0.65). https://t.co/TsV0Pr6V8m
-
-
Mashup Score: 0SMARCA4-deficient lung carcinoma is an aggressive tumor highly infiltrated by FOXP3+ cells and neutrophils - 2 year(s) ago
The switch/sucrose-non-fermenting (SWI/SNF) complex functions as a tumor suppressor and mutations in at least one of its subunits have been demonstrated in 20% of human cancers [1]. The SMARCA4 gene encodes BRG1, one of the two ATPase subunits of the SWI/SNF complex. SMARCA4 inactivating mutations are described in two thoracic tumors: SMARCA4-deficient undifferentiated tumor (SD-UT, formerly…
Source: Lung CancerCategories: Hematologists1, Latest HeadlinesTweet-
SMARCA4-deficient NSCLC- incidence- 5–10%, aggressive tumor, poor prognosis and non-response to anti-PD1 inhibitors https://t.co/Q7qnjguAes
-
-
Mashup Score: 1
Standard first-line chemotherapy for patients with small cell lung cancer (SCLC) consists of a platinum salt (carboplatin or cisplatin) in combination with etoposide [1,2]. Recently, atezolizumab [3] or durvalumab [4] plus carboplatin/etoposide showed improved survival compared to chemotherapy alone, and both have been approved by the US FDA as first-line therapy. However, therapeutic options are…
Source: Lung CancerCategories: Hem/Oncs, Latest HeadlinesTweet-
Antitumor activity of lurbinectedin in second-line small cell lung cancer patients who are candidates for re-challenge with the first-line treatment https://t.co/SnV7CI9wNC
-
-
Mashup Score: 1Exhaled Breath Condensate (EBC) analysis of circulating tumour DNA (ctDNA) using a lung cancer specific UltraSEEK Oncogene panel - 2 year(s) ago
Lung cancer is responsible for the highest cancer-related mortality worldwide.[1] Overall survival in advanced disease has traditionally been poor[2]but has improved in recent years in response to the developments of new treatments[3,4]. An improved understanding of the aberrant molecular biomarkers arising from somatic gene mutations that drive malignancy has led to the development of agents…
Source: Lung CancerCategories: Hem/Oncs, Latest HeadlinesTweet-
Proof of concept study @LungCaJournal on exhaled breath condensate for biomarker testing for NSCLC. Compared favorably to plasma and tissue NGS for major targets. Need more details on specificity and type of mutations identified but promising data! #LCSM https://t.co/nck9k5r2dT
-
-
Mashup Score: 2Patient perception of burden of disease and treatment preferences in non-small cell lung cancer: Results from a European survey - 2 year(s) ago
Non-small cell lung cancer (NSCLC) is one of two main subtypes of lung cancer, accounting for 84% of all cases [1]. NSCLC is considered difficult to treat owing to its aggressiveness and resistance to current therapies [2]. However, with the advancement of molecular biomarker testing, specific genetic alterations have been identified that enable personalized treatment leading to improved outcomes…
Source: Lung CancerCategories: Hem/Oncs, Latest HeadlinesTweet-
This report from a patient survey in Europe @LungCaJournal highlights the ongoing need for improved communication about biomarkers, clinical trials, and financial toxicity. Most pts prefer oral to IV and interesting insights into pill burden here. #LCSM https://t.co/BEEQtHnuaS
-
-
Mashup Score: 11
The role of low-dose CT scans for lung cancer and the selection of appropriate populations to screen are ongoing areas of exploration in cancer prevention. Screening parameters are based on models that consider the incidence of lung cancer in the population, the risks associated with overdiagnosis, the rates of risk factors, survival benefit, healthcare cost considerations, and healthcare policy…
Source: Lung CancerCategories: Latest Headlines, Oncologists2Tweet-
Check out the latest publication from the #DumaLab ⬇️⬇️⬇️ 💡Adjust, don’t avoid: The need for risk-based CT screening in nonsmoking populations It's time to see lung cancer screening from an additional perspective. Lead by @NishwantS https://t.co/RlELhHHp2Z https://t.co/LSxItWAWMN
-
-
Mashup Score: 1
Standard first-line chemotherapy for patients with small cell lung cancer (SCLC) consists of a platinum salt (carboplatin or cisplatin) in combination with etoposide [1,2]. Recently, atezolizumab [3] or durvalumab [4] plus carboplatin/etoposide showed improved survival compared to chemotherapy alone, and both have been approved by the US FDA as first-line therapy. However, therapeutic options are…
Source: Lung CancerCategories: Hem/Oncs, Latest HeadlinesTweet-
Antitumor activity of lurbinectedin in second-line small cell lung cancer patients who are candidates for re-challenge with the first-line treatment @OncoAlert https://t.co/adVm0s81RS
-
-
Mashup Score: 0
The therapeutic management of advanced non–small cell lung cancer (NSCLC) has profoundly improved in recent years, and the treatment algorithms are not only limited to conventional cytotoxic chemotherapies, but also molecular-targeted therapies and immunotherapy [1,2]. Approximately two-thirds of patients with NSCLC harbor actionable oncogenic driver mutations, including epidermal growth factor…
Source: Lung CancerCategories: Hem/Oncs, Latest HeadlinesTweet-
Report @LungCaJournal that high PDL1 expression in #ALK NSCLC associated with worse outcomes. #PDL1 high (23% of pts) had shorter PFS and shorter OS. Surrogate for specific variants or co-mutations? This does not equate to immunotherapy efficacy though! https://t.co/mlHbOmSChK
-
@jamecancerdoc @OncoAlert @myESMO Antitumor activity of lurbinectedin in second-line small cell lung cancer patients who are candidates for re-challenge with the first-line treatment https://t.co/E8K8HxJZxa